Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    sobi | Sanfilippo Syndrome
Previous Study | Return to List | Next Study

A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03811028
Recruitment Status : Recruiting
First Posted : January 21, 2019
Last Update Posted : January 28, 2019
Sponsor:
Information provided by (Responsible Party):
Swedish Orphan Biovitrum

Tracking Information
First Submitted Date  ICMJE December 17, 2018
First Posted Date  ICMJE January 21, 2019
Last Update Posted Date January 28, 2019
Actual Study Start Date  ICMJE January 23, 2019
Estimated Primary Completion Date December 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 18, 2019)
Safety will be measured by adverse events frequencies (by type and severity) [ Time Frame: Continuously from the informed consent is signed through study completion, summarized over 18 months. ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03811028 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 18, 2019)
  • The observed serum concentration immediately before the start of the next infusion of SOBI003 (CPre-infusion) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The observed serum concentration at the end of infusion of SOBI003 (CEnd of inf) [ Time Frame: Weeks 38, 52, 78 and 104 ]
    The study is an extension study, thus there might be serum concentrations from the previous study at the first assessment (Week 38) in the study
  • The time of the end of the infusion of SOBI003 (tEnd of inf) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The maximum observed serum concentration (Cmax) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The time at which the maximum serum concentration is observed (tmax) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The minimum observed serum concentration (CTrough) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • Clearance (CL) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The area under the plasma concentration-time curve from time 0 to last sample (AUC0-168h) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • The half-life (t1/2) [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • SOBI003 concentration in cerebrospinal fluid [ Time Frame: Weeks 52 and 104 ]
  • Proportion of patients having anti-drug antibodies in serum [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • Proportion of patients having anti-drug antibodies in cerebrospinal fluid [ Time Frame: Weeks 52 and 104 ]
  • Change from baseline in Heparan Sulfate concentration in cerebrospinal fluid [ Time Frame: Weeks 52 and 104 ]
  • Change from baseline in Heparan sulfate concentration in serum [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • Change from baseline in Heparan sulfate concentration levels in urine [ Time Frame: Weeks 38, 52, 78 and 104 ]
  • Neurocognitive Development Quotient [ Time Frame: Weeks 52 and 104 ]
    Quotient between age equivalent score and age, 0 - 100%, where high values are desirable. The age equivalent score represent the age of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed by the Bayley Scales of Infant and Toddler Development®, third edition cognitive subtest or the Kaufman Assessment Battery for Children, Second edition. The Bayley Scales of Infant and Toddler Development-Third Edition is an individually administered test designed to assess developmental functioning of infants and toddlers. The Bayley-III assesses development in five areas: cognitive, language, motor, social-emotional, and adaptive behavior. The Kaufman Assessment Battery for Children (K-ABC) is a clinical instrument for assessing cognitive development.
  • Change from baseline in Neurocognitive Development Quotient [ Time Frame: Week 52 and 104 ]
    Quotient between age equivalent score and age, 0 - 100%, where high values are desirable. The age equivalent score represent the age of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed by the Bayley Scales of Infant and Toddler Development®, third edition cognitive subtest or the Kaufman Assessment Battery for Children, Second edition. The Bayley Scales of Infant and Toddler Development-Third Edition is an individually administered test designed to assess developmental functioning of infants and toddlers. The Bayley-III assesses development in five areas: cognitive, language, motor, social-emotional, and adaptive behavior. The Kaufman Assessment Battery for Children (K-ABC) is a clinical instrument for assessing cognitive development.
  • Age-equivalence score as assessed either by the BSID-III, cognitive subtest, or the KABC-II. [ Time Frame: Week 52 and 104 ]
    The age equivalent score represents the age in months of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed either by the Bayley Scales of Infant and Toddler Development®, third edition, (BSID-III) cognitive subtest or the Kaufman Assessment Battery for Children, Second edition (KABC-II) depending on chronological age of the subject. Quotient between age equivalent score and age, 0 - 100%, where high values are desirable. The BSID-III is an individually administered test designed to assess developmental functioning of infants and toddlers. The BSID-III assesses development in five areas: cognitive, language, motor, social-emotional, and adaptive behavior. The KABC-II is a clinical instrument for assessing cognitive development. The unit and measurement is the same in both scales (BSID-III and KABC-II): Age-equivalent score.
  • Change from baseline in Age-equivalence score as assessed either by the BSID-III, cognitive subtest, or the KABC-II. [ Time Frame: Week 52 and 104 ]
    The age equivalent score represents the age in months of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed either by the Bayley Scales of Infant and Toddler Development®, third edition, (BSID-III) cognitive subtest or the Kaufman Assessment Battery for Children, Second edition (KABC-II) depending on chronological age of the subject. Quotient between age equivalent score and age, 0 - 100%, where high values are desirable. The BSID-III is an individually administered test designed to assess developmental functioning of infants and toddlers. The BSID-III assesses development in five areas: cognitive, language, motor, social-emotional, and adaptive behavior. The KABC-II is a clinical instrument for assessing cognitive development. The unit and measurement is the same in both scales (BSID-III and KABC-II): Age-equivalent score.
  • Age-equivalence score as assessed by VABS-II [ Time Frame: Week 52 and 104 ]
    The age equivalent score represent the age in months of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed by Vineland™ Adaptive Behavior Scales, Expanded Interview Form, Second edition (VABS-II). The Vineland is designed to measure adaptive behavior of individuals from birth to age 90. The Vineland-II contains 5 domains each with 2-3 subdomains. The main domains are: Communication, Daily Living Skills, Socialization, Motor Skills, and Maladaptive Behavior.
  • Change from baseline in Age-equivalence score as assessed by VABS-II [ Time Frame: Week 52 and 104 ]
    The age equivalent score represent the age in months of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed by Vineland™ Adaptive Behavior Scales, Expanded Interview Form, Second edition (VABS-II). The Vineland is designed to measure adaptive behavior of individuals from birth to age 90. The Vineland-II contains 5 domains each with 2-3 subdomains. The main domains are: Communication, Daily Living Skills, Socialization, Motor Skills, and Maladaptive Behavior.
  • Gray matter volume [ Time Frame: Week 52 and 104 ]
    Grey matter contains most of the brain's neuronal cell bodies. The grey matter includes regions of the brain involved in muscle control, and sensory perception such as seeing and hearing, memory, emotions, speech, decision making, and self-control. The gray matter volume will be measured by volumetric magnetic resonance imaging (MRI).
  • Change from baseline in gray matter volume [ Time Frame: Week 52 and 104 ]
    Grey matter contains most of the brain's neuronal cell bodies. The grey matter includes regions of the brain involved in muscle control, and sensory perception such as seeing and hearing, memory, emotions, speech, decision making, and self-control. The gray matter volume will be measured by volumetric magnetic resonance imaging (MRI).
  • Pediatric Quality of Life Inventory (PedsQL™) total score [ Time Frame: Week 52 and 104 ]
    Pediatric Quality of Life Inventory (PedsQL™) is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. Lower scores indicate better functioning. Min score = 0, and max score = 144.
  • Change from baseline in Pediatric Quality of Life Inventory (PedsQL™) total score [ Time Frame: Week 52 and 104 ]
    Pediatric Quality of Life Inventory (PedsQL™) is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. Lower scores indicate better functioning. Min score = 0, and max score = 144.
  • PedsQL™ Family Impact Module total score [ Time Frame: Week 52 and 104 ]
    Pediatric Quality of Life Inventory (PedsQL™) is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The Total Score is the sum of all 36 items in the test divided by the number of items answered. Higher scores indicate better functioning.
  • Change from baseline in PedsQL™ Family Impact Module total score [ Time Frame: Week 52 and 104 ]
    Pediatric Quality of Life Inventory (PedsQL™) is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The Total Score is the sum of all 36 items in the test divided by the number of items answered. Higher scores indicate better functioning.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Official Title  ICMJE An Open, Single-arm, Multicenter Extension Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Brief Summary MPS IIIA, also known as Sanfilippo A, is an inherited lysosomal storage disease (LSD). MPS IIIA is caused by a deficiency in sulfamidase, one of the enzymes involved in the lysosomal degradation of the glycosaminoglycan (GAG) heparan sulfate (HS). The natural course of MPS IIIA is characterized by devastating neurodegeneration with initially mild somatic involvement. The aim of the present study is to assess the safety, tolerability and efficacy of long-term SOBI003 treatment. SOBI003 is a chemically modified recombinant human (rh) Sulfamidase developed as an enzyme replacement therapy (ERT).
Detailed Description

This is an open, single-arm, multicenter extension study to assess the safety, tolerability and efficacy of long-term SOBI003 treatment in pediatric MPS IIIA patients. The study is an extension of the First in Human (FIH) SOBI003-001 study, allowing continuous treatment of SOBI003 for up to 2 years. Study patients who complete Week 24 of the FIH study (SOBI003-001) will be invited to continue to Week 25 in the extension study.

When entering the extension study, these patients will receive the highest dose that has been declared safe in the ongoing FIH study (SOBI003-001). Upon completion of the FIH study, an analysis aimed at selecting the dose for forthcoming studies will take place. Once the dose has been selected, this dose will be applied to all patients enrolled in the extension study. The total duration of the extension study for an individual patient is 80 weeks, resulting in a total of 104 weeks (2 years) of SOBI003 treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Sanfilippo Syndrome Type A (MPS IIIA)
Intervention  ICMJE Drug: SOBI003
weekly i.v. infusion
Other Name: Modified recombinant human sulphamidase
Study Arms  ICMJE Experimental: SOBI003

SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.

SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined.

Intervention: Drug: SOBI003
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 18, 2019)
9
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2021
Estimated Primary Completion Date December 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Completion of study SOBI003-001
  • Informed consent obtained from the patient´s legally authorized representative

Exclusion Criteria:

  • If, in the opinion of the investigator, there are patient specific safety concerns that contraindicates further treatment with SOBI003
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Months to 78 Months   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anders Bröijersén, MD +46 760 011576 anders.broijersen@sobi.com
Contact: Kristin Önnestam, MSC +46 760 011594 kristin.onnestam@sobi.com
Listed Location Countries  ICMJE Turkey,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03811028
Other Study ID Numbers  ICMJE SOBI003-002
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Swedish Orphan Biovitrum
Study Sponsor  ICMJE Swedish Orphan Biovitrum
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Paul Harmatz, MD Children´s Hospital and Research Center, Oakland
PRS Account Swedish Orphan Biovitrum
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP